Background {#Sec1}
==========

Since early 1950s, researchers began to investigate sexual dysfunction. And absolutely most of studies focused on erectile dysfunction, premature ejaculation et al. male sexual issue \[[@CR1], [@CR2]\]. However, with increasing socioeconomic status in current society, female health is not an ignorable concern nowadays \[[@CR3], [@CR4]\]. Until recent decade, researchers began to shift attention to this topic, and the first female "Viagra"-[Flibanserin](https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=0ahUKEwjo5oPf5-7VAhUC0oMKHUYqDPwQFghjMAE&url=http%3A%2F%2Fwww.addyi.com%2F&usg=AFQjCNF3RBP3awB86u1hJMvujVAyxJmCCg) was approved by American FDA in 2016, but there was a dearth of literature about Chinese female sexual dysfunction (FSD).

Lack of, or significantly decreased sexual interest or arousal manifested by at least three of the following characteristics should be identified as FSD: (i) absent or decreased interest in sexual activity; (ii) absent or decreased sexual or erotic thoughts or fantasies; (iii) no or decreased initiation of sexual activity and typically unreceptive to a partner's attempts to initiate; (iv) absent or decreased sexual excitement or pleasure during sexual activity in almost all or all (approximately 75%--100%) sexual encounters (in identified situational contexts or, if generalized, in all contexts); (v) absent or decreased sexual interest or arousal in response to any internal or external sexual or erotic cues (eg, written, verbal, or visual); or (vi) absent or decreased genital or non-genital sensations during sexual activity in almost all or all (approximately 75%--100%) sexual encounters (in identified situational contexts or, if generalized, in all contexts) \[[@CR5]\]. According to different studies, prevalence of FSD varies from 25%, by Kammerer-Doak, to 63%, by Rogers \[[@CR6]\]. So it is a common entity besetting women in worldwide. However, the incidence is uncertain in China, especially after the optimal cutoff value was determined by Ma and his team \[[@CR7]\] in 2014 basing on the Chinese Han ethnic, the biggest population in China.

FSD is a multifactorial problem \[[@CR8], [@CR9]\]. Previous literatures reported psychological factors (irritation, depression and anxiety et al.) and socioeconomic factors (income, education background and living condition) is associated with FSD \[[@CR10]--[@CR12]\]. Meanwhile, endocrinal messengers e.g. prolactin \[[@CR13]\], [gonadal hormone](http://dict.cn/gonadal%20hormone) \[[@CR14], [@CR15]\] usually has impact on female sexual function.

Additionally, thyroid disorder\--hypothyroidism is believed to associate with FSD \[[@CR10], [@CR16]\]. But relationship between subclinical hypothyroidism (ScHt) and FSD is still not clear because of paucity of evidence. Previously, Ergenekon observed that a significantly more women with ScHt of TSH values \>10 mU/L had sexual dysfunction \[[@CR16]\]. By contrast, Lee et al. demonstrated that ScHt is not a risk factor for FSD in Korean middle-aged women \[[@CR17]\].

Due to the controversies in the topic, a preliminary screening study exploring risk factor for FSD with optimal diagnostic value for Chinese was conducted firstly in China.

Methods {#Sec2}
=======

This hospital-based survey was conducted in Health Promotion Center of West China Hospital between June and December of 2015. The health promotion center provided routine check-ups for each member. As described in previous study \[[@CR18]\], all of approached women who meet criteria was included in the final analysis.

The diagnosis of Hashimoto thyroiditis referred to Caturegli P's review \[[@CR19]\]. Included subjects were divided into two groups\--ScHT and control group, according to thyroid hormone tests. The reference of thyroid hormone and antibody was the same in previous study \[[@CR18]\].

Validated by Sun et al. in 2011 \[[@CR20]\], Chinese Version of the FSFI (CVFSFI) was adopted to evaluate female sexual function. According to research of Ma et al. in 2014 \[[@CR7]\], female sexual dysfunction was defined as a CVFSFI score ≤ 23.45. And 2.7, 3.15, 4.05, 3.8, 3.6 and 3.8 was chosen as optimal cutoff values for low desire/arousal/lubrication/orgasm/satisfaction/sexual pain in the research. In the study, psychological status was evaluated by second version of Beck Depression Inventory (BDI-II), as described in previous study \[[@CR18]\].

SPSS version 21 (SPSS Inc., Chicago, IL) was used in the data analysis. Variables were presented as the mean ± standard deviation or median (interquartile range) and compared by t-test or U-test. Chi-square test was used to compare frequency for categorical variables. Risk factor was identified by logistic regression. *P* value less than 0.05 indicates significance.

Results {#Sec3}
=======

During the enrollment period, a total of 1314 women approved to participate in the study. And 1265 women completed the CVFSFI questionnaires in high quality. Then 146 participants were excluded since overt hyper- or hypothyroidism. Finally, 1119 participants came into final analysis, including 168 ScHt participants (15.0%). The baseline were shown in Table [1](#Tab1){ref-type="table"}.Table 1Basic characters comparison between subclinical hypothyroidism and control groupScHT (*N* = 168)Control (*N* = 951)*P* valueAge39.2 ± 7.638.5 ± 7.70.548Height158.2 ± 4.8158.9 ± 5.20.416Weight55.3 ± 8.154.7 ± 6.60.561BMI22.1 ± 3.021.7 ± 2.40.304fT35.0 ± 0.65.0 ± 0.70.999fT416.4 ± 2.117.1 ± 2.20.045Systolic pressure109.6 ± 15.7108.6 ± 13.10.631Diastolic pressure69.9 ± 10.269.0 ± 8.90.500TSH5.4(4.7, 6.5)2.3(1.7, 2.9)\<0.001TPOab9.0(5.2, 41.5)7.9(5.2,13.1)0.124Tgab19.6(14.9, 149.9)17.9(13.8,23.5)0.022Hypertension (Y/N)12/156 (7.14%)47/904 (4.94%)0.259Diabetes (Y/N)6/162 (3.57%)32/919 (3.36%)0.819Hashimoto Thyroiditis (Y/N)24/144 (14.28%)50/901 (5.25%)\<0.001Perimenopause (Y/N)24/144 (14.28%)201/750 (21.14%)0.047Menopause (Y/N)6/162 (3.57%)28/923(2.94%)0.627Smoking0.603 Never168 (100%)944 (99.26%) Current07Alcohol consumption0.446 Never162 (96.43%)900 (94.64%) Rarely6 (3.57%)51 (5.36%)Marital status0.016 Married168 (100%)921 (96.85%) Unmarried030 (3.15%)Education status0.401  ≤ Middle School81 (48.21%)423 (44.48%)  ≥ University87 (51.79%)528 (55.52%)Income (RMB/year)0.607  ≤ 40,00030 (17.86%)207 (21.77%) 40,000--100,000132 (78.57%)693 (72.87%)  ≥ 100,0006 (3.57%)51 (5.36%)Physical activity0.552 No36 (21.43%)174 (18.30%) Rarely45 (26.79%)276 (29.02%) Frequently87 (51.79%)501 (52.68%)Depression status0.727 No132 (78.57%)774 (81.39%) Light33 (19.64%)147 (15.46%) Medium3 (1.79%)30 (3.15%) Severe00Parity^a^1 (1,1)1 (1,1)0.162*ScHT* subclinical hypothyroidism, *fT3* [free triiodothyronine](http://www.baidu.com/link?url=tNNvxDtf265MJ7KI7ZlJGE0GO7YX42jK8aW6R1vZCvOkDOuSHLnQ5EMaGqTRX5fVJXJh99WUPKhXqE70pGxzf6l0YhO2-TiDFUk5rpH1Ffoi7JTS4iulVEnsWPHhVrH1), *fT4* free thyroxine, *BMI* body mass index*P* \< 0.05 shows significant difference^a^Compared by U-test

Significantly more participants with Hashimoto Thyroiditis (HT) in ScHT group than control, 14.28% (24/168) vs 5.25% (50/951) respectively, (*p* \< 0.001). Table [1](#Tab1){ref-type="table"}. Besides, significantly more participants were perimenopaused and married in ScHT group, compared with control group, *p* = 0.047, 0.016, respectively.

With respect to FSFI score, a total of 297 participants (26.5%) were at risk for FSD (FSFI score ≤ 23.45), including 36 in ScHT group (21.4%) and 261 in control group (27.4%), no significant difference (*p* = 0.108). Incidence of low desire/ low arousal/ low lubrication/ low orgasm/ low satisfaction and sexual pain in ScHT group was 14.3%, 17.9%, 21.4%, 21.4%, 23.2% and 23.2% respectively. Comparatively, it was 17.7%, 16.0%, 19.6%, 22.1%, 22.7% and 23.7% respectively in control group. Therefore, two groups had no significant difference in FSD and subtype of FSD, as shown in Table [2](#Tab2){ref-type="table"}.Table 2CVFSFI score and FSD comparison between subclinical hypothyroidism and control groupScHT (*N* = 168)Control (*N* = 951)*P* valueTotal CVFSFI Score25.8 ± 3.925.7 ± 3.90.869Desire3.5 ± 0.843.4 ± 0.80.466Arousal3.9 ± 1.03.9 ± 0.90.844Lubrication4.9 ± 0.94.9 ± 0.90.919Orgasm4.3 ± 0.94.4 ± 0.80.628Satisfaction4.6 ± 0.94.6 ± 0.80.780Pain4.6 ± 1.04.5 ± 0.90.622FSD (CVFSFI total score ≤ 23.45)36(21.4%)261(27.4%)0.108Low Desire (≤2.7)24(14.3%)168(17.7%)0.319Low Arousal (≤3.15)30(17.9%)152(16.0%)0.571Low Lubrication (≤4.05)36(21.4%)186(19.6%)0.600Low Orgasm (≤3.8)36(21.4%)210(22.1%)0.920Low Satisfaction (≤3.6)39(23.2%)216(22.7%)0.921Sexual Pain (≤3.8)39(23.2%)225(23.7%)1.000*ScHT* subclinical hypothyroidism, *CVFSFI* Chinese Version of Female Sexual Function Index, *FSD* female sexual dysfunction*P* \< 0.05 shows significant difference

Adjusted by cofounding variables, it was clear to find that Age was a common risk factor for FSD. Adjusted odd ratio (OR) was 1.086 (1.021, 1.155), 1.087 (1.023, 1.155), 1.118 (1.050, 1.191) and 1.059 (1.001, 1.120) in Desire, Arousal, Lubrication and FSD, respectively, Table [3](#Tab3){ref-type="table"}. Likely, Depression was common risk factor for all types of FSD. And it is interesting to see that higher Income (40,000--100,000 RMB/year) was a protective variable for nearly all types of FSD. However, it would impair female sexual ability when income \>100,000 RMB/year. BMI was identified as risk factor for Low Desire (1.281 \[1.121, 1.463\], *p* \< 0.001). Besides, we failed to found a determined relationship between ScHT with any type of FSD. Table [3](#Tab3){ref-type="table"}.Table 3Risk factor identification by Enter Multivariate analysisLow DesireLow ArousalLow LubricationLow OrgasmLow SatisfactionSexual PainFSDVariablesOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueAge1.086 (1.021, 1.155)0.0081.087 (1.023, 1.155)0.0071.118 (1.050, 1.191)0.0011.019 (0.964, 1.078)0.5001.039 (0.981, 1.101)0.1880.994 (0.935, 1.056)0.8371.059 (1.001, 1.120)0.045Income (40,000--100,000 RMB/year)0.443 (0.212, 0.927)0.0310.397 (0.195, 0.810)0.0110.298 (0.148, 0.597)0.0010.551 (0.289, 1.049)0.0700.328 (0.174, 0.620)0.0010.576 (0.305, 1.090)0.0900.308 (0.164, 0.579)\<0.001ScHT0.874 (0.272, 2.807)0.8211.045 (0.34, 3.209)0.9391.716 (0.575, 5.121)0.3330.700 (0.247, 1.979)0.5011.064 (0.387, 2.925)0.9040.412 (0.128, 1.325)0.1370.529 (0.175, 1.603)0.260HT0.442 (0.088, 2.216)0.3211.122 (0.319, 3.940)0.8581.099 (0.286, 4.223)0.8911.377 (0.424, 4.473)0.5940.453 (0.092, 2.227)0.3300.290 (0.061, 1.381)0.1200.681 (0.200, 2.312)0.537fT40.989 (0.851, 1.151)0.8900.906 (0.775, 1.058)0.2131.089 (0.941, 1.260)0.2530.970 (0.850, 1.107)0.6530.863 (0.750, 0.993)0.0400.946 (0.830, 1.079)0.4110.94 (0.824, 1.072)0.357Tgab1.001 (1.000, 1.002)0.0781.001 (1.000, 1.002)0.1681.000 (0.997, 1.002)0.6911.001 (1.000, 1.002)0.0620.999 (0.997, 1.001)0.4131.000 (0.999, 1.001)0.6681.000 (1.000, 1.001)0.378TSH0.944 (0.795, 1.122)0.5160.931 (0.769, 1.127)0.4610.953 (0.789, 1.151)0.6181.097 (0.927, 1.298)0.2810.965 (0.816, 1.140)0.6711.202 (0.986, 1.465)0.0681.031 (0.863, 1.231)0.739Depression status (medium risk)2.260 (0.5, 10.205)0.2898.048 (1.853, 34.950)0.00520.601 (3.649, 116.316)0.0013.402 (0.882, 13.119)0.0754.948 (1.188, 20.609)0.0281.716 (0.42, 7.012)0.45233.035 (3.553, 307.108)0.002Education background (≥University)1.534 (0.72, 3.267)0.2680.610 (0.289, 1.286)0.1941.233 (0.593, 2.563)0.5740.916 (0.471, 1.779)0.7950.848 (0.431, 1.668)0.6340.783 (0.404, 1.517)0.4680.783 (0.404, 1.517)0.468Perimenopause0.875 (0.344, 2.231)0.7800.546 (0.217, 1.376)0.2000.754 (0.303, 1.877)0.5451.264 (0.532, 3.006)0.5962.618 (1.061, 6.458)0.0371.173 (0.507, 2.718)0.7091.173 (0.507, 2.718)0.709BMI1.281 (1.121, 1.463)\<0.0011.086 (0.933, 1.223)0.3391.103 (0.964, 1.262)0.1551.075 (0.958, 1.207)0.2170.954 (0.847, 1.076)0.4461.067 (0.947, 1.203)0.2851.067 (0.947, 1.203)0.285Smoking2.325 (0.241, 22.401)0.4651.224 (0.076, 19.821)0.8871.014 (0.059, 17.577)0.9923.103 (0.463, 20.787)0.2434.057 (0.615, 26.775)0.1463.024 (0.392, 23.342)0.2893.024 (0.392, 23.342)0.289*ScHT* subclinical hypothyroidism, *HT* Hashimoto Thyroiditis, *fT4* free thyroxine, *OR* odd ratio, *CI* confidence interval, *FSD* female sexual dysfunction*P* \< 0.05 shows significant difference

Discussion {#Sec4}
==========

To our limited knowledge, it is the first study to explore the relationship between thyroid hormone and female sexual dysfunction (FSD) in China. Though Lee et al. firstly has proved subclinical hypothyroidism (ScHT) is not risk factor for FSD \[[@CR17]\], they failed to set the relationship between thyroid hormone and FSD. At the same time, our study also is the first screening research based on the Ma et al.'s optimal cutoff value after 2014 \[[@CR7], [@CR20]\].

In our current study, it is interesting to know that the incidence of subclinical hypothyroidism and female sexual dysfunction is 15.0% and 26.5% respectively. As we know, the prevalence of subclinical hypothyroidism is higher than previous reports \[[@CR21], [@CR22]\], which is mainly resulted from iodine deficiency. Sichuan province locates at western inside mountainous land of China, and element iodine is relative deficient, so government forces to sell iodized salt for 16 years. Incidence of iodine deficiency-related thyroid disease decreases much \[[@CR23]\]. Meanwhile, there was no significant difference between ScHT group and control group in Female Sexual Function Index (FSFI) score (25.8 ± 3.9 vs 25.7 ± 3.9). ScHT was not a risk factor for FSD even though after adjustment, which confirmed the Lee's findings \[[@CR17]\].

Our study suggested that less than one third---26.5% of women was beset by FSD. Reportedly, Laumann et al. found that 43% of American women was at risk for FSD \[[@CR24]\]. 52% of interviewed women had at least one type of FSD in an Iranian population-based study \[[@CR25]\]. The number in Egypt is 52.8% according to Ibrahim et al. report \[[@CR26]\]. In all, the difference was mainly resulted from different ethnics, cutoff value and conservative culture background\-\--Chinese women are reluctant to talk it with physicians. On the other hand, it coincided with researches in Iran, Turkey, Medellin and Malaysia, which reported the prevalence was 31.5%, 26.1%, 30%, 29.6% respectively \[[@CR27]--[@CR30]\]. Though previous research conducted by Sefa Resim et al. found that education level of male and female was found to be significantly related to FSD \[[@CR31]\], we found higher education (≥University) was not protective factor for FSD. This may be resulted from different classifier---in Sefa Resim's report, participants was divided into illiterate, schooling \< 8 years and \>8 years.

Subclinical hypothyroidism, affecting 10% of population, is more frequently detected in women than men, and advanced age \[[@CR21], [@CR32]\]. Due to the influence of thyroid hormone on lipid metabolism, subclinical hypothyroidism is proved to be risk factor for heart failure, coronary heart disease and dyslipidemia \[[@CR33]--[@CR37]\]. But the research about the relationship between subclinical hypothyroidism and FSD is rare. In previous study, Atis G et al. reported that a significant percent of women with clinic hypothyroidism and subclinical hypothyroidism with TSH values \> 10 mIU/L had sexual dysfunction. Subclinical hypothyroidism, however, with TSH values \< 10 mIU/L did show this trend \[[@CR16]\]. It shared the same view with our study, because only 6 participant with TSH more than10 mIU/L were enrolled in our study. Thus TSH in absolutely most of participants was lower than 10 mIU/L in the present study. And it is found that ScHT is not risk factor for any type of FSD. Therefore, the result, in fact, kept consistent with Atis G's.

Several limitations are inevitable in our study. First of all, it is limited by the location. West China Hospital locates southwestern part of China. People intend to be more conservative than in Beijing or costal region, especially to sexual life or experience, because of comparatively less developed economy. Reportedly, Sun et al. found prevalence of FSD was 52% in Beijing, but they used DSM-IV-TR, not FSFI as screening tool. And the result in our study hardly has general representativeness for a whole population due to uneven development of economy and culture. Therefore, we look forward more researchers could focus on this topic. Secondly, short of diversity is inevitable, because the absolutely most of participants come from urban region. The result may be a little different when adopted in urban and suburban area. Therefore, a multicenter screening study is needed. Thirdly, due to the limitation of health examination programs, sex hormone, like testosterone, estradiol, luteinizing hormone et al., cannot be collected. An extensive study involving sex hormone is conducting in department.

Conclusions {#Sec5}
===========

In conclusion, the prevalence of female sexual dysfunction and subclinical hypothyroidism in China, southwestern part of China exactly, was 26.5% and 15.0%, respectively. And subclinical hypothyroidism is not risk factor for any type of FSD.

BDI

:   Beck Depression Inventory

CVFSFI

:   Chinese version of the female sexual function index

FSD

:   Female sexual dysfunction.
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